PhotoPharmics Overview

  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $2.5M
Latest Deal Amount
  • Investors
  • 5

PhotoPharmics General Information

Description

Developer of non-invasive therapies designed to improve the lives of patients suffering from neurological disorders and addictions. The company's therapies offer chrono-biological treatments for Parkinson's disease as well as medical edge-lit devices used for the treatment of neurological disorders, enabling medical institutions to restore the health of patients suffering from Parkinson's disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Drug Discovery
Biotechnology
Primary Office
  • 987 South 500 East
  • Suite 110
  • American Fork, UT 84003
  • United States
+1 (801) 000-0000

PhotoPharmics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

PhotoPharmics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 11-Dec-2020 $2.5M 000.00 Completed Clinical Trials - General
6. Later Stage VC (Series B) 30-Apr-2020 0000 Cancelled Clinical Trials - General
5. Early Stage VC (Series A) 11-Oct-2019 00.00 000.00 000.00 Completed Clinical Trials - General
4. Seed Round 10-Feb-2017 00.000 000.00 000.00 Completed Clinical Trials - General
3. Seed Round 19-Jun-2015 00.000 0000 Completed Startup
2. Early Stage VC (Series A) 01-May-2015 $8M $10.7M 0000 Completed Startup
1. Seed Round 04-Jan-2013 $2.73M $2.73M 00.000 Completed Startup
To view PhotoPharmics’s complete valuation and funding history, request access »

PhotoPharmics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00.00 00 00.00 00.00
Seed 0,000,000 00.000000 00.00 00.00 00 00.00 00.00
To view PhotoPharmics’s complete cap table history, request access »

PhotoPharmics Executive Team (3)

Name Title Board Seat Contact Info
Kent Savage Co-Founder, President, Chief Executive Officer & Board Member
Daniel Adams Co-Founder, Science Officer & Board Member
Karl Kieburtz MD Chief Medical Officer
To view PhotoPharmics’s complete executive team members history, request access »

PhotoPharmics Board Members (4)

Name Representing Role Since
Daniel Adams PhotoPharmics Co-Founder, Science Officer & Board Member 000 0000
Gavin Christensen Kickstart Seed Fund Board Member 000 0000
Kent Savage PhotoPharmics Co-Founder, President, Chief Executive Officer & Board Member 000 0000
You’re viewing 3 of 4 board members. Get the full list »

PhotoPharmics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PhotoPharmics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Park City Angels Angel Group Minority 000 0000 000000 0
UpStart Ventures (Salt Lake City) Venture Capital Minority 000 0000 000000 0
Josh Hughes Angel (individual) Minority 000 0000 000000 0
Kickstart Seed Fund Venture Capital Minority 000 0000 000000 0
Salt Lake Life Science Angels Angel Group Minority 000 0000 000000 0
To view PhotoPharmics’s complete investors history, request access »